Warren Remedies commences commercial production of APIs

Moderna posts Q4 2023 revenue at US$ 2.8 billion

Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance

AstraZeneca completes acquisition of Icosavax

The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody

Ginkgo, SaponiQx to discover and manufacture next-gen vaccine adjuvants

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination

Nucala approved in China for use in severe asthma with an eosinophilic phenotype

Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data

Lupin launches Varenicline Tablets in US

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway

Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi

The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired

WHO issues warning on the surge of new age gateway devices among children

Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use